Plaque Psoriasis

New research, comparable with that of the NAVIGATE trial, was conducted and showed strong results for the use of guselkumab for psoriasis patients.

Experts in dermatology share practice pearls to advanced practice providers and community dermatologists for the management of plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, discusses unmet needs in the treatment landscape of plaque psoriasis.

Douglas DiRuggiero, DMSc, PA-C, reviews how deucravacitinib impacts the quality of life for patients with plaque psoriasis.

Recent findings indicated that patients with new-onset psoriasis may see positive results from switching to secukinumab treatment.

Dermatology experts discuss BMI and other background comorbidities that can impact IL-23 inhibitors when treating plaque psoriasis.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss year long term efficacy and safety data regarding the use of IL-23 inhibitors in patients with moderate to severe plaque psoriasis.

This recent analysis highlighted an association between anxiety disorder and psoriasis in both children and adult patients.

Darren West, MPAS, PA-C, shares how often follow-up is required with deucravacitinib therapy in plaque psoriasis.

Andrea Nguyen, PA-C, MS, provides an overview of the safety considerations of deucravacitinib for the treatment of plaque psoriasis.

Dermatology experts discuss how IL-23 inhibitors fit into the current treatment landscape for plaque psoriasis.

George Han, MD, PhD, provides an overview of the long-term persistence of different biologic treatment options for plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, shares clinical pearls for clinicians managing patients with plaque psoriasis.

Matthew T. Reynolds, PA-C, comments on how evaluating treatment profiles, comorbidities, age, and population can help the clinician understand plaque psoriasis and improve management strategies.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, discuss implications of real-world data on the use of IL-23 inhibitors in treatment of plaque psoriasis for older patients.

Experts in dermatology discuss what patients to consider treating with deucravacitinib, as well as comment on the comparative safety and efficacy of other therapies.

Experts in dermatology discuss the importance of deucravacitinib being an expansion of oral treatment modalities for plaque psoriasis, as well as the long-term data.

In her interview with HCPLive, Armstrong spoke on new data presented at Fall Clinical Dermatology on bimekizumab, deucravacitinib, and upadacitinib.

An interview segment with Armstrong in which she elaborates on some of the main points made from her presentation on psoriasis treatments.

Neal Bhatia, MD, discusses the impact of treatment mode of delivery on patient adherence and treatment selection for IL-23 inhibitors for plaque psoriasis.

Dermatology experts provide an overview of tildrakizumab, guselkumab, and risankizumab, agents approved for patients with plaque psoriasis.

The sex differences, as well as other demographic differences, between GPP patients were assessed in a recent research letter.

Experts in psoriasis examine the implications of long-term data for IL-23 inhibitors, especially in patients who have not responded to initial treatment of plaque psoriasis.

Jayme Heim, MSN, FNP-BC, and Matthew T. Reynolds, PA-C, comment on potential safety concerns and adverse events regarding the use of IL-23 inhibitors as well as the long-term safety and efficacy of these therapies in plaque psoriasis.

Jayme M. Heim, MSN, FNP-BC, reviews deucravacitinib as an oral treatment for moderate to severe plaque psoriasis, describing its unique mechanism of action.

Douglas DiRuggiero, DMSc, PA-C, discusses factors that contribute to switching a patient with plaque psoriasis from a topical to a systemic agent.

In a summary of a symposium from the 2021 EADV Congress, the writers describe patients’ difficulties in living with psoriasis and adhering to treatments.

A recent study found that deucravacitinib saw positive results for moderate-to-severe adult plaque psoriasis patients.

Brad Glick, DO, AOCD, George Han, MD, PhD, and Neal Bhatia, MD, discuss communicating with patients about their plaque psoriasis treatment options.

George Han, MD, PhD, discusses the practical considerations of escalating treatment to the use of traditional oral systemic agents such as apremilast or methotrexate.